Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected
neuritis, apoptotic neurons, and reduced inflammation in cortical
multiple sclerosis lesions. Ann Neurol 50:389 – 400, 2001. 25.
7. Cifelli A, Arridge M, Jezzard P, Esiri MM, Palace J, Matthews
PM. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 52:650 – 653, 2002.
8. Giovannoni G, Lai M, Kidd D, Thorpe JW, Miller DH, Thomp- 26.
son AJ, Keir G, Feldmann M, Thompson EJ. Daily urinary ne- opterin excretion as an immunological marker of disease activity
in multiple sclerosis. Brain 120:1–13, 1997.
27.
9. Berger T, Rubner N, Schautzer F, Egg R, Ulmer H, Mayringer I
et al. Antimyelion antibodies as a predictor of clinically definite
multiple sclerosis after a first demyelinating event. N Engl J Med
349:139 –145, 2003.
10. Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F,
28.
Heppner F et al. The peripheral benzodiazepine binding site in the
brain in multiple sclerosis. Quantitative in vivo imaging of mi- croglia as a measure of disease activity. Brain 123:2321–2337,
2000.
29.
11. Debruyne JC, Versijpt J, van Laere KJ, de Vos F, Keppens J,
Strijckmans K et al. PET visualization of microglia in multiple
sclerosis patients using [11C]PK11195. Eur J Neurol 10:257–
264, 2003.
12. McDonald WI, Compston A, Edan G, Goodkin D, Hartung H-P,
30.
Lublin FD et al. Recommended diagnostic criteria for multiple
sclerosis: guidelines from the international panel on the diagnosis
of multiple sclerosis. Ann Neurol 50:121–127, 2001.
13. Katz D, Taubenberger J, Cannella B, McFarlin D, Raine C,
31.
McFarland H. Correlation between magnetic resonance imaging
findings and lesion development in multiple sclerosis. Ann Neurol
34:661– 669, 1993.
14. Bruck W, Bitsch A, Kolenda H, Bruck Y, Stiefel M, Lassmann H.
32.
Inflammatory central nervous system demyelination: correlation
of magnetic resonance imaging findings with lesion pathology.
Ann Neurol 42:783–793, 1997.
15. Grossman RI, Gonzales-Scarano F, Atalas SW, Galetta S, Silber-33.
berg DH. Multiple sclerosis: gadolinium enhancement in MR
imaging. Radiology 169:117–122, 1986.
16. Thorpe JW, Kidd D, Moseley IF, Kendall BE, Thompson AJ,
MacManus DG et al. Serial gadolinium enhanced MRI of the
brain and spinal cord in early relapsing-remitting multiple scle- 34.
rosis. Neurology 46:373–378, 1996.
17. Hickman SJ, Toosy AT, Miszkiel KA, Jones SJ, Altmann DR,
MacManus DG et al. Predicting visual recovery following optic
neuritis: a clinical, electrophysiological and magnetic resonance
imaging study. Mult Scler 9(Suppl 1):S95, 2003. 35.
18. Youl BD, Turano G, Miller DH, Towell AD, MacManus DG,
Moore SG et al. The pathophysiology of optic neuritis: an association of gadolinium leakage with clinical and electrophysiolog- 36.
ical deficits. Brain 114:2437–2450, 1991.
19. Kappos L, Moeri D, Radue EW, Schoetzau A, Schweikert K,
Barkhof F et al. Predictive value of gadolinium-enhanced mag- 37.
netic resonance imaging for relapse rate and changes in disability
or impairment in multiple sclerosis: a meta-analysis. Lancet 353:
964 –969, 1999.
20. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice G,
Libonati LA, Wilmer-Hulme A, Dalton C, Miszkiel K, O'Connor 38.
PW. A controlled trial of natalizumab for relapsing multiple
sclerosis. N Engl J Med 348:15–23, 2003.
21. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ,
Miller DH. A longitudinal study of abnormalities on MRI and
disability from multiple sclerosis. N Engl J Med 346:158 –164, 39.
2002.
22. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors
and progression of irreversible disability in multiple sclerosis: an
amnesic process. Brain 126:770 –782, 2003.
23. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and 40.
progression of multiple sclerosis. N Engl J Med 343:1430 –1438,
2000.
24. Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HF. 41.
Serial gadolinium-enhanced magnetic resonance imaging scans in
patients with early, relapsing-remitting multiple sclerosis: impli-
